Hepatocellular Carcinoma Interpreting the Evidence to Improve Clinical Outcomes

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer death worldwide, and rates are increasing each year. The majority of HCC is diagnosed in advanced stages, where potentially curative therapy is ineffective, and outcomes are poor. In recent years, several targeted therapies and immunotherapies have emerged that have drastically changed outcomes in advanced HCC.

This program will cover current and emerging treatment options for advanced HCC, how to make patient-personalized treatment decisions, and how to manage treatment emergent adverse events to ensure optimal outcomes.

Jointly provided by the Potomac Center for Medical Education and Rockpointe

This activity is supported by an educational grant from Bayer US.

Click here for the PCME Privacy Policy